ArticleEuropean journal of medical research2025
TIGD6 in gastric cancer: exploring its prognostic value and therapeutic potential through molecular and clinical investigations.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) predominantly contributes to cancer mortality, with adenocarcinomas accounting for more than 95% of incidences. Early detection improves survival, but most cases are diagnosed at advanced stages due to subtle symptoms and rapid progression. The role of TIGD6 in GC is unclear.
methodsWe analyzed TIGD6 expression using TCGA data and correlated it with clinical features and outcomes in GC patients. Bioinformatics tools, including GSEA and single-cell sequencing, were used to elucidate TIGD6's role in GC. In the GC cell lines AGS and HGC-27, TIGD6 was knocked down using RNA interference, and subsequent in vitro experiments were conducted to evaluate cell proliferation, migration, and invasion capabilities.
resultsThe expression of TIGD6 was markedly elevated in GC tissues relative to normal tissues (p < 0.001). Higher TIGD6 levels were linked to residual tumors (p = 0.027), history of reflux (p = 0.019), and antireflux treatment (p = 0.0012). Increased TIGD6 expression was associated with decreased overall survival (OS, p = 0.009) and disease-specific survival (DSS, p = 0.008), and it served as an independent predictor of worse OS (p = 0.043). Knocking down TIGD6 in GC cells suppressed proliferation, migration, and invasion, while enhancing apoptosis through modulation of the Hedgehog signaling pathway.
conclusionTIGD6 is overexpressed in GC and linked to unfavorable outcomes. It could potentially function as a biomarker and therapeutic target for this malignancy. Future studies should validate its clinical relevance and explore its detailed molecular mechanisms. Collectively, this study provides the first functional, mechanistic, and immune-phenotypic characterization of TIGD6 in GC, positioning it as a dual biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.